GlassScriptPhysician profile
Amod Amritphale
NPI 1053675157
$18,564.93
in general payments reported to CMS, 2019-2025
24 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $289 · 2021: $188 · 2022: $1,996 · 2023: $1,737 · 2024: $1,778 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,050 · Food and Beverage: $5,368 · Travel and Lodging: $4,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,050.00 |
| Food and Beverage | $5,368.29 |
| Travel and Lodging | $4,200.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $11,249.73 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $2,018.66 | 2019-2024 | (Bq9) Coronary Ivus, (Br4) Coronary Undivided, (6391) Nexcimer |
| Biotronik INC. | $1,516.39 | 2022-2025 | Orsiro Mission, Nhancer Rx |
| Amgen INC. | $465.01 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $429.05 | 2019-2022 | |
| Abbott Laboratories | $411.99 | 2019-2024 | Diamondback Coronary, Tacticath Ablation Catheter, Sensor Enabled, Na |
| Cardiovascular Systems INC. | $400.62 | 2019-2023 | Diamondback Coronary |
| Boston Scientific Corporation | $365.20 | 2022-2024 | Avvigo Guidance System |
| Teleflex LLC | $342.72 | 2025 | Orsiro Mission, Trapliner |
| Abiomed | $342.44 | 2022-2025 | Impella |
| Medtronic, INC. | $189.51 | 2023-2025 | Corevalve Evolut R |
| Heartflow, INC. | $175.86 | 2025 | |
| Sanofi-Aventis U.S. LLC | $150.43 | 2019 | |
| Angiodynamics, INC. | $122.59 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $117.28 | 2020-2023 | Camzyos |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.26 | 2019-2024 | Lifevest |
| Terumo Medical Corporation | $43.30 | 2019 | |
| Edwards Lifesciences Corporation | $27.59 | 2025 | Sapien 3 Ultra Resilia |
| Bard Peripheral Vascular, INC. | $25.02 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.03 | 2019 | |
| Kestra Medical Technology Services, INC. | $22.24 | 2025 | Assure Wcd |
| Lantheus Medical Imaging, INC. | $14.95 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.79 | 2020 | |
| Portola Pharmaceuticals, LLC | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amod Amritphale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.